SARS-CoV-2 Serological Studies around the Globe

Dear Colleagues,

A novel coronavirus (2019-nCoV) associated with human to human transmission and severe human infection has been recently reported from the city of Wuhan in the Hubei province in China. A total of 13.4 and 0.58 million cases and deaths, respectively, were reported up to 16 July 2020. Given the high transmissibility and the extensive geographic dispersal of the virus as well as the absence of effective treatments or a vaccine, public health measures provide the only way to prevent SARS-CoV-2 transmission. The contribution of asymptomatic individuals to onward transmissions is significant and has been highlighted in previous studies. Given that SARs-CoV-2 is a new virus, we need to better understand the levels and the duration of protective immunity in patients with different severities of the disease (i.e., asymptomatic, mild and severe symptoms, hospitalized patients, ARDS symptoms), the levels of exposure to SARS-CoV-2 in highly vulnerable people and populations of special interest (i.e., healthcare workers, migrants, intravenous drug users, populations with limited access to health care facilities, HIV/AIDS patients), the parameters associated with the presence of antibodies, as well as the estimated performance of antibody testing in panels with known SARS-CoV-2 status. All of this information will be valuable across different geographic areas and different time periods.

Prof. Angelos Hatzakis
Dr. Dimitrios Paraskevis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.